Lipid Metabolism Pathway Genes and Lung Cancer: ACADSB rs12220683G>C Is Associated with Better Survival Outcome in Patients with Non-Small Cell Lung Cancer.

IF 2.5 3区 医学 Q3 ONCOLOGY
Oncology Pub Date : 2024-01-01 Epub Date: 2023-08-01 DOI:10.1159/000533156
Seung Soo Yoo, Sook Kyung Do, Jin Eun Choi, Hyo-Gyoung Kang, Mi Jeong Hong, Jang Hyuck Lee, Won Kee Lee, Young Woo Do, Eung Bae Lee, Ji Eun Park, Sun Ha Choi, Hyewon Seo, Yong Hoon Lee, Jaehee Lee, Shin Yup Lee, Seung Ick Cha, Chang Ho Kim, Jae Yong Park
{"title":"Lipid Metabolism Pathway Genes and Lung Cancer: ACADSB rs12220683G&gt;C Is Associated with Better Survival Outcome in Patients with Non-Small Cell Lung Cancer.","authors":"Seung Soo Yoo, Sook Kyung Do, Jin Eun Choi, Hyo-Gyoung Kang, Mi Jeong Hong, Jang Hyuck Lee, Won Kee Lee, Young Woo Do, Eung Bae Lee, Ji Eun Park, Sun Ha Choi, Hyewon Seo, Yong Hoon Lee, Jaehee Lee, Shin Yup Lee, Seung Ick Cha, Chang Ho Kim, Jae Yong Park","doi":"10.1159/000533156","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Altered lipid metabolism has been reported to be associated with prognosis in multiple cancers. This study aimed to investigate the association of polymorphisms in lipid metabolism pathway genes with survival outcomes in patients with surgically resected non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>In total, 744 patients with surgically resected NSCLC (380 in the discovery cohort and 364 in the validation cohort) were included in this study. The association between 176 polymorphisms of lipid metabolism pathway genes and the clinical outcomes of NSCLC patients was analyzed.</p><p><strong>Results: </strong>Among the polymorphisms investigated, ACADSB rs10902859G&gt;A was associated with significantly better overall survival (OS) in the discovery, validation, and combined cohorts. ACADSB rs10902859G&gt;A was located in the repressed region and had strong linkage disequilibrium (D' = 1.00 and r2 = 0.94), with rs12220683G&gt;C located in the H3K4me3 peak region, which indicates the presence of active promoters. ACADSB rs12220683G&gt;C was also associated with better OS in the discovery, validation, and combined cohorts (in a dominant model; adjusted hazard ratio [aHR] = 0.53, 95% confidence interval [CI] = 0.30-0.94, p = 0.03; aHR = 0.37, 95% CI = 0.15-0.89, p = 0.03; and aHR = 0.47, 95% CI = 0.29-0.75, p = 0.002, respectively). In vitro luciferase assay demonstrated that the promoter activity of ACADSB was significantly increased in the rs12220683 variant C allele compared with that in the wild G allele (p = 3 × 10-5).</p><p><strong>Conclusion: </strong>These results suggest that ACADSB rs12220683G&gt;C increases promoter activity and that increased ACADSB expression may result in better OS in patients with surgically resected NSCLC.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000533156","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Altered lipid metabolism has been reported to be associated with prognosis in multiple cancers. This study aimed to investigate the association of polymorphisms in lipid metabolism pathway genes with survival outcomes in patients with surgically resected non-small cell lung cancer (NSCLC).

Methods: In total, 744 patients with surgically resected NSCLC (380 in the discovery cohort and 364 in the validation cohort) were included in this study. The association between 176 polymorphisms of lipid metabolism pathway genes and the clinical outcomes of NSCLC patients was analyzed.

Results: Among the polymorphisms investigated, ACADSB rs10902859G>A was associated with significantly better overall survival (OS) in the discovery, validation, and combined cohorts. ACADSB rs10902859G>A was located in the repressed region and had strong linkage disequilibrium (D' = 1.00 and r2 = 0.94), with rs12220683G>C located in the H3K4me3 peak region, which indicates the presence of active promoters. ACADSB rs12220683G>C was also associated with better OS in the discovery, validation, and combined cohorts (in a dominant model; adjusted hazard ratio [aHR] = 0.53, 95% confidence interval [CI] = 0.30-0.94, p = 0.03; aHR = 0.37, 95% CI = 0.15-0.89, p = 0.03; and aHR = 0.47, 95% CI = 0.29-0.75, p = 0.002, respectively). In vitro luciferase assay demonstrated that the promoter activity of ACADSB was significantly increased in the rs12220683 variant C allele compared with that in the wild G allele (p = 3 × 10-5).

Conclusion: These results suggest that ACADSB rs12220683G>C increases promoter activity and that increased ACADSB expression may result in better OS in patients with surgically resected NSCLC.

脂质代谢途径基因与肺癌:ACADSB rs12220683G>C 与非小细胞肺癌患者更好的生存结果相关。
简介据报道,脂质代谢改变与多种癌症的预后有关。本研究旨在探讨脂质代谢通路基因的多态性与手术切除的非小细胞肺癌(NSCLC)患者生存预后的关系:本研究共纳入了744名手术切除的非小细胞肺癌患者(发现队列380人,验证队列364人)。研究分析了176个脂质代谢通路基因多态性与NSCLC患者临床结局之间的关联:结果:在所调查的多态性中,ACADSB rs10902859G>A与发现队列、验证队列和联合队列中较好的总生存期(OS)显著相关。ACADSB rs10902859G>A位于抑制区,并与rs12220683G>C位于H3K4me3峰区(这表明存在活跃的启动子)具有强关联不平衡(D'=1.00,r2=0.94)。ACADSB rs12220683G>C还与发现队列、验证队列和联合队列中较好的OS相关(在显性模型中;调整危险比[aHR]=0.53,95%置信区间[CI]=0.30-0.94,p=0.03;aHR=0.37,95% CI=0.15-0.89,p=0.03;aHR=0.47,95% CI=0.29-0.75,p=0.002)。体外荧光素酶试验表明,与野生 G 等位基因相比,rs12220683 变异 C 等位基因中 ACADSB 的启动子活性显著增加(p = 3 × 10-5):这些结果表明,ACADSB rs12220683G>C 增加了启动子活性,增加 ACADSB 的表达可能会改善手术切除 NSCLC 患者的 OS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信